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Abstract FSH inactivity due to secondary hypoglycosyla-
tion has been suggested as a potential mechanism for pri-
mary ovarian insufficiency in classic galactosemia. To
investigate the role of FSH and to gain insight in the timing
of the damage, ovarian stimulation tests were performed and
data on ovarian imaging collected. Fifteen patients with
primary ovarian insufficiency underwent ovarian stimula-
tion with gonadotropins. Only one patient showed a normal
increase in estradiol level, all the others had a low or no
estradiol response. Anti-Müllerian hormone measurement in
all girls and women showed levels below the detection limit
of 0.10 μg/l. Ovarian volumes were evaluated by MRI in 14
patients and compared to age matched controls, prepubertal
controls and postmenopausal controls. The ovarian volumes
of the galactosemic girls were smaller than those of the age
matched controls (p00.001) and the prepubertal ovaries (p0
0.008), and did not differ significantly from postmenopausal
ovarian volumes (p00.161). In conclusion we found no
evidence that FSH inactivity plays a role in primary ovarian
insufficiency in classic galactosemia. Moreover, ovarian
imaging results point to an early onset of ovarian failure in
this disease.
Introduction
Primary ovarian insufficiency (POI) is frequent in classic
galactosemia (Holton et al 2001; Kaufman et al 1981).
According to female patients and their parents, this complica-
tion represents the greatest psychological burden for women
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with this disorder (Bosch et al 2004).Most patients experience
hypergonadotropic hypogonadism, with subsequent absent or
delayed pubertal development, amenorrhea/oligomenorrhea
and decreased fertility. Usually they are treated with exoge-
nous estrogens to prevent complications of hypoestrogenism.
The etiology underlying POI in classic galactosemia is not
yet fully understood, and several mechanisms have been
postulated including direct toxicity of metabolites, altered
gene expression or aberrant function of hormones and or
receptors due to glycosylation abnormalities (Rubio-Gozalbo
et al 2009). It is also conceivable that not one, but the different
mechanisms acting in unison are responsible for this clinical
picture. Galactose or galactose metabolites could induce dam-
age, either through a direct or an indirect toxic effect on the
ovary, with chronically increased apoptosis leading to ovarian
atrophy (Kaufman et al 1986). The galactose burden in this
disease also seems to alter gene expression (Coman et al 2010;
Lai et al 2008). In addition, classic galactosemia leads sec-
ondarily to glycosylation abnormalities of complex mole-
cules, possibly through inhibition of galactosyltransferases
by Gal-1-P. Glycosylation is often crucial for an adequate
function of these complex molecules. (Charlwood et al
1998; Dobbie et al 1990; Haberland et al 1971; Jaeken et al
1992; Ornstein et al 1992; Petry et al 1991; Staubach et al
2011; Stibler et al 1997; Sturiale et al 2005).
FSH, a glycoprotein, is highly dependent on glycosylation
(Combarnous 1992) for its function, and theoretically, an
altered FSH function due to hypoglycosylation in this disease,
could lead to primary ovarian insufficency. Studies on the
glycosylation pattern of FSH in women with classic galacto-
semia and POI, show different results. Prestoz et al (1997)
found in their study hypoglycosylated FSH isoforms in these
patients, whereas our group found a normal FSH isoform
pattern (Gubbels et al 2011). If FSH inactivity is a key mech-
anism causing POI in this disease, one would expect a rise in
estradiol when exogenous, active FSH is given.
There is also uncertainty about when exactly the damage
occurs. Observations in animal models suggest a prenatal
onset of the lesion. Rats exposed to galactose prenatally had
a decreased number of oocytes (Chen et al 1981), and rats with
pre- and postnatal galactose exposure had overall ovarian
dysfunction (Bandyopadhyay et al 2003). In humans however,
normal ovarian histology has been observed in two neonates
(Levy 1996; Levy et al 1984), as well as normal appearance of
the ovaries in a girl at age seven (Kaufman et al 1981),
whereas later in adolescence she had atrophic ovaries.
In this study, a group of adolescent and adult female
classic galactosemia patients was evaluated using ovarian
stimulation and ovarian imaging to address the following
questions:
– Is there evidence for FSH dysfunction?
– When does the damage to the ovaries occur?
Patients and methods
Patients
A total of 24 female galactosemia patients, aged 6–43, were
included. All studies were approved by our IRB. Patients
were invited to participate through our outpatient clinic and
by the Dutch Galactosemia Association from March 2007 –
October 2009 and volunteered with informed consent. The
inclusion criterion for these studies was confirmed classic
galactosemia diagnosis (GALT enzyme activity measure-
ment and/or GALT gene mutational analysis). The patients
who participated in the stimulation protocols had all POI
defined as amenorrhea for at least four months before the
age of 40 and confirmed by two separate measurements of
FSH in the postmenopausal range with at least 1 month
between measurements (Nelson et al 2009). Patient charac-
teristics are summarized in Table 1.
Control patients in three control groups (age matched,
pre-pubertal and postmenopausal) for the MRI studies were
sought anonymously from the database of MRI scans in our
hospital. We ensured that the imaging used for control
patients was comparable to the galactosemia ovary protocol.
The majority of the control patients underwent an abdomi-
nal MRI for Crohn’s disease. Patients with known malfor-
mations of the reproductive tract or diseases known to affect
the reproductive system were excluded. For every galacto-
semia patient, the two available controls that were closest in
age to the patient at the time of the MRI were selected as
age-matched controls. In all but one case, the age of the
matched controls differed <1 year from the age of the
patient. The only exception was a patient aged 8.9 years.
In this case, as no other controls were available for her, the
accepted matched controls were 7.0 years. The prepubertal
control patients were 0.3 to 6.9 years old (mean 3.2 years),
and their ovaries and uterus had no signs of pubertal devel-
opment. All available suitable prepubertal patients were
selected for this control group. In the Netherlands the aver-
age age at menopause is 51.5+3.9 years (Brand 1978).
Therefore, the postmenopausal control patients were all
>60 years old (mean 63.2 years; range 60.7-65.9 years).
We selected the most recent suitable patients.
Stimulation tests
Different stimulation tests were performed using a model
wherein the insights gained in the previous test were applied
to the following test.
1 EFORT
An exogenous FSH ovarian reserve test (EFORT) was
performed in three patients with 300 IU recombinant FSH,
Gonal-F (Serono Europe Ltd., Houten, The Netherlands). In
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the women who used oral contraceptives (OC) or hormone
replacement therapy (HRT) prior to the test, their medication
was withdrawn for seven days to eliminate external hormon-
al influences. Patients undergoing this test had subsequently
a high endogenous FSH. Before the administration of the
FSH and 24 hours after, 17β-estradiol was measured. An
increase in 17β-estradiol >0.11 nmol/l is considered a
positive response (Fanchin et al 1994).
2 Three day stimulation with FSH and LH
Nine patients were stimulated with a three day pro-
tocol that combined daily subcutaneous administration
of FSH and LH (225 IU of Gonal-F and 150 IU of
recombinant LH, Luveris (Serono Europe Ltd., Houten,
The Netherlands)), or 225 IU of human Menopausal
Gonadotropin (hMG), Menopur (Ferring B.V., Hoofddorp,
The Netherlands)). Preceding the first injection, and 24 hours
after the last one, 17β-estradiol was measured. To ensure that
the patient’s own, possibly inactive, FSH could not block the
FSH receptor (Combarnous 1992), all patients continuously
used OC in the three weeks previous to and during the
stimulation to inhibit their endogenous FSH production and
ensure low levels of endogenous FSH.
3 Twenty day stimulation with FSH and LH
Three patients were stimulated with a 20 day protocol
while using OC. During the first ten days, they received
150 IU of Menopur s.c. (kindly provided by Ferring BV) per
Table 1 Patient characteristics
Nr Age (years) Mutation GALT-activity
(nmol/mmol Hb/hr












1 19 Q188R/ Q188R 8 Yes (12) 14 65.6 Stimulation, MRI
2 29 Q188R/ Q188R 10 No 16 83.0 Stimulation
31 24 Q188R/S135W 3.7 (0.7 %) ‘Neonatally’
diagnosed
Yes (16) 19 NA Stimulation
4 22 Q188R/ Q188R 21.2 (3.7 %) 3 No 6 73.0 Stimulation
5 23 Q188R/ Q188R 7 No 1.5 30.0 Stimulation
62 36 Q188R/ K285N 4.5 (0.8 %) 15 Yes (16) 27 89.0 Stimulation
7 21 Q188R/ Q188R 18.3 (3.1 %) 0 Yes (12) 12 34.0 Stimulation, MRI
8 21 Q188R/Q188R 0.4 (0.1 %) 11 Yes (13) 17 48.5 Stimulation
9 24 Q188R/ Q188R 5.3 (0.9 %) 30 Yes (12) 15 >50 Stimulation
10 23 L195P/ L195P 21.8 (3.7 %) 14 No 12 57.5 Stimulation
11 27 L195P/ X380C3 14.5 (2.5 %) NA No 12 NA Stimulation
12 15 Q188R/ Q188R NA No 12 82.5 Stimulation, MRI
13 15 IVSC/ IVSC 6.2 (1.1 %) 6 No 11 43.7 Stimulation
14 16 Q188R/Q188R 6 No 2 46.8 Stimulation, MRI
15 19 Q188R/ Q188R 3.9 (0.7 %) NA No Unknown NA Stimulation, MRI
16 18 Q188R/ Q188R NA Yes (15) Unknown NA MRI
17 16 Q188R/Q188R 9 No 10 54.2 MRI
18 11 L195P/ K229N 6 No 10 67.6 MRI
19 11 Q188R/Q188R 9 - - - MRI
20 9 Q188R/Q188R 1.0 (0.2 %) NA - - - MRI
21 9 Q188R/Q188R 23 - - - MRI
22 14 Q188R/ Q188R 4.7 (0.8 %) 0 No Unknown NA MRI
23 9 Q188R/Q188R 1.3 (0.2 %) 0 Yes (12) - NA MRI





1 3 pregnancies: 1 stillbirth, 2 healthy children
2 4 pregnancies: 2 miscarriages, 2 healthy children
3 Bosch et al 2005
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day. If no response was seen, the study was continued with
225 IU Menopur s.c. per day during ten more days. 17β-
estradiol was measured on days 1, 9, 11, 19 and 21. The
rationale behind this longer stimulation period was that a 3-




Sera from the patients were collected following standard
procedures. Commercially available immunofluorometric
assays (IFMAs) were used for the determination of LH
and FSH (PerkinElmer’s AutoDelfia, Turku, Finland). For
17-β-estradiol, we used a fluorometric immunoassay (FIA)
(PerkinElmer’s AutoDelfia, Turku, Finland). AMH concen-
trations were quantitatively determined in a random sample
(not during gonadotropin stimulation) using a commercially
available assay from DSL (Webster, Texas, USA). The
obtained laboratory values were compared to the control
range used in Maastricht University Medical Center for
female patients in the age group of our patients.
Statistical analyses
Patient characteristics, such as age at diagnosis/treatment,
spontaneous menarche versus induced pubertal develop-
ment, genotype and GALT enzyme activity were used to
try to create a predictive model for estradiol response. SPSS
version 16.0 was used for analysis.
Ovarian imaging
MRI
Magnetic resonance imaging was performed with a 1.5 T
system. Transverse, sagital and coronal T2-weighted 2 mm
slices covered the area between the umbilicus and symphysis
pubis. Additional T1-weighted transverse slices and
T2-weighted transverse slices with fat-suppression were
performed. Ovarian volume was calculated by using the
formula of an ellipsoid (length x width x depth x π/6).
Statistical analysis
Distribution of the samples was evaluated by plotting the
data. As the samples were not normally distributed, non-
parametric statistical tests were used. The ovarian volumes
of the galactosemic girls were compared to age matched
controls by using the Wilcoxon signed ranks test. For this,
the mean volume of the two ovaries of each patient was
compared to the mean volume of the four ovaries of the
control patients. The mean ovarian volume of the galacto-
semia patients was compared to the mean volume of the
prepubertal and postmenopausal control groups using the
Mann–Whitney test. For analysis, in the cases where the
ovaries could not be detected, we used the detection limit of
0.2×0.2×0.2×π/600.004 cc, because 2 mm was both the
smallest visualized ovarian dimension, as well as the




The results of the stimulation tests are summarized in
Table 2. No patient responded to the EFORT, but three out
of nine patients showed an increase in 17β-estradiol con-
centration after stimulation with the 3 day regime of FSH
and LH and two of three showed a response after 21 day
stimulation. Only one (3 day) patient, however, showed a
normal response of >0.3 nmol/l. Spontaneous menarche
versus induced pubertal development, genotype and GALT
enzyme activity were not predictive of an estradiol response
during the simulation tests.
Ovarian imaging
Compared to age-matched controls, the ovaries of galacto-
semic girls and women were significantly smaller (p0
0.001). The ovaries of the galactosemia patients were also
significantly smaller (p00.008) than those of control prepu-
bertal girls but did not differ significantly (p00.161) from
postmenopausal controls. The median ovarian volume was
<0.004 cm3 (undetectable) (range <0.004-3.4 cm3) in galac-
tosemia patients, 0.9 cm3 (range <0.004-3.7 cm3) in prepu-
bertal girls and <0.004 cm3 (range <0.004-1.1 cm3) in the
postmenopausal control group. The age matched and prepu-
bertal control patients showed evidence of ovarian activity
(multiple cysts) whereas in the galactosemic patients and in
postmenopausal controls, evidence of activity was seen only
rarely.
Hormone assays
All patients had AMH levels below the detection limit of
0.10 μg/l . In the three patients that underwent 21 day
stimulation, AMH was measured at the same time as 17β-
estradiol, but no increases in AMH were seen. Spontaneous
baseline FSH and LH levels in the non-prepubertal girls and
women were in the postmenopausal range. FSH rose as
expected during the stimulation tests, LH remained
around the same level, as its half-life is shorter. For
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the 21 day stimulation, Menopur was used (hCG substitutes
LH activity). All baseline 17β-estradiol levels were low for
the patient’s age.
Discussion
The response to FSH stimulation was evaluated in a
group of adolescent and adult female classic galacto-
semia patients. If endogenous FSH dysfunction due to
abnormal glycosylation is a key mechanism in this
disease, the patients are expected to have a significant
response to FSH stimulation analogous to patients with
FSH beta subunit mutations (Matthews et al 1993;
Rabin et al 1972). However, only one patient showed
a significant response to FSH administration supporting
the proposed mechanism that in the ovaries of classic
galactosemia patients the numbers of follicles that can
respond to exogenous gonadotropins is very low. These
findings are in line with reports of normal bioactivity of
endogenous FSH in galactosemia (Kaufman et al 1981;
Sanders et al 2009). Interestingly, two patients (numbers
5 and 12) had a spontaneous menstruation for the first
time within two months after the ovarian stimulation
test, while they were still on their continuously dosed
estrogen-only HRT. Another patient became pregnant
two months after an EFORT (Gubbels et al 2009). This
might be a coincidence and reflect sporadic ovulation or
reflect that a follicle in a very early stage was stimu-
lated to develop under FSH administration. The two
month window is the needed time to progress from a
secondary to an antral follicle (Gougeon 1986). Sporadic
follicle maturation despite POI (Gubbels et al 2008) occurs
and during the studies we witnessed this process. Where an
MRI in patient 16 did not reveal detectable ovarian tissue, a
transvaginal ultrasound performed five months later showed a
clearly visible ovary with a cyst suggestive of a follicle of
2 cm diameter. This patient is currently 20 years old and
spontaneously pregnant.
Regarding the question when the damage to the ovary
occurs, imaging of the ovaries in all galactosemic girls and
women revealed low mean ovarian volumes, similar to the
ovaries of the postmenopausal women. The prepubertal
ovaries of the controls were also significantly larger than
the ovaries of the galactosemic group. These data are in
agreement with ovarian damage occurring early in life.
Demarcation of the time window in which ovarian damage
occurs is very important in view of fertility maintenance
strategies. Cryopreservation of ovarian tissue or vitrification
of oocytes are current fertility preservation techniques in-
creasingly applied in other diseases. The chances of fertility
using these procedures depend on the ovarian reserve, and
the use of these methods for this disease might only be a
realistic option at a very early age and/or for selected
candidates.
Within the limitations of the study because of the small
and heterogeneous sample with a wide age range, we think
this paper adds valuable information to the existing knowl-
edge on POI in female classic galactosemia patients. We
have not found evidence for FSH inactivity as the primary
mechanism causing POI and damage to the ovary occurs
early in life.





* Statistically significant response
Patient Age (years) Δ17β-estradiol (nmol/l)




1 19 0.0 - -
2 29 0,0 - -
3 24 0,0 - -
4 22 0.0 - -
5 23 0.0 0.0 -
6 36 0.0 0.1* -
7 21 0.0 0.0 -
8 21 0.0 0.0 -
9 24 0.0 0.0 0.0
10 23 - - 0.1*
11 27 - - 0.2*
12 15 - 0.0 -
13 15 - 0.1* -
14 16 - 0.0 -
15 19 - 0.3* -
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